| Marker Therapeutics is a clinical-stage immuno-oncology company. Co. focuses on the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, as well as develops DNA expression technology. Co. is developing vaccines that target candidate breast cancer(s), colorectal cancer(s), ovarian cancer(s) and non-small cell lung cancer(s). Co.'s three primary technology platforms include: a licensed vaccine for the treatment of HER2/neu+ breast cancer; a licensed vaccine for treating breast and ovarian cancers; and a wholly owned DNA expression vaccine technology (Polystart) for treating various cancers or infectious disease. We show 10 historical shares outstanding datapoints in our TPIV shares outstanding history coverage, used to compute TPIV market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TPIV market cap history over the course of time is important for investors
interested in comparing TPIV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TPIV versus a peer is one thing; comparing
TPIV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TPIV can fluctuate over the course of history.
With this page we aim to empower investors researching TPIV by allowing them to research the TPIV market cap history.